ME 105

Drug Profile

ME 105

Alternative Names: Anti-IL-5 vaccine - Pharmexa; Asthma vaccine - Pharmexa; AutoVac IL-5 vaccine - Pharmexa

Latest Information Update: 25 Jun 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S
  • Class Vaccines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
  • 29 Nov 2002 Suspended - Preclinical for Asthma in Denmark (unspecified route)
  • 05 Apr 2002 A preclinical study has been added to the Obstructive airways disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top